- 英文名称
- Vorapaxar sulfate
- 分子式
- C29H35FN2O8S
- 分子量
- 590.66
- 中文别名
- ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-氟苯基)吡啶-2-基)乙烯基)-1-甲基-3-氧代十二氢萘并[2,3-c]呋喃-6-基)氨基甲酸乙酯 硫酸盐; 硫酸沃拉帕沙; 沃拉帕沙; 硫酸沃拉帕莎; 硫酸沃诺帕沙; N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-氟苯)-2-吡啶基]乙烯基]十二氢-1-甲基-3-氧代萘[2,3-C]呋喃-6-基]-氨基甲酸乙酯; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate sulfate; Ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]vinyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate sulfate (1:1); vorapaxar monosulfate; Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, sulfate (1:1); ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate,sulfuric acid; Zontivity; SCH 530348; N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-Methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbaMic Acid Ethyl Ester Sulfate; SCH 530348 (H2SO4 Salt); vorapaxar impurity A; SCH-530348; SCH530348
- 用途
- 生命科学领域作为口服有效的凝血酶受体(PAR-1)拮抗剂；医药领域作为抗血小板药物，用于治疗和预防动脉粥样硬化血栓形成；用于有心肌梗死或外周动脉疾病史患者以减少血栓性心血管事件；针对急性冠状动脉综合征（不稳定的心绞痛/非ST段抬高型心肌梗塞）和高危患者的心血管事件进行二级预防的III期临床试验。
